Effect of Type 2 Diabetes Mellitus on the Pharmacokinetics of Metformin in Obese Pregnant Women

August 2012 in “ Clinical Pharmacokinectics ”

Cláudia de Oliveira Baraldi, Elaine Christine Dantas Moisés, Tereza Cristina de Carvalho, Nilson Antunes, Vera Lucia Lanchote, Geraldo Duarte, Ricardo de Carvalho Cavalli

Type 2 Diabetes Mellitus T2DM metformin polycystic ovary syndrome PCOS pharmacokinetics insulin diabetes glucophage diabetes medication

TLDR Type 2 diabetes does not change how metformin works in obese pregnant women, so dosage adjustments are not needed.

The study investigated how Type 2 Diabetes Mellitus (T2DM) affects the pharmacokinetics of metformin in obese pregnant women, comparing eight non-diabetic obese pregnant women with PCOS and nine obese pregnant women with T2DM. Both groups were on a regimen of 850 mg of metformin every 12 hours during the third trimester. The study found no significant differences in pharmacokinetic parameters between the two groups, suggesting that T2DM and insulin use do not alter the pharmacokinetics of metformin in these patients. Therefore, the study concluded that there is no need to adjust the metformin dosage for pregnant women with PCOS and T2DM based on these findings.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

4025 citations, December 2003 in “Human Reproduction”

The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.

Related Community Posts Join

6 / 1000+ results

community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

in Research 830 upvotes 6 months ago

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

community Detailed 6 months update for FUE HT and 4 years of FIN-MIN journey

in Progress Pictures 192 upvotes 1 year ago

A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.

community Convinced dad to get into minox 3 months ago and fin 2 months ago

in Is this regrowth? 824 upvotes 7 months ago

A user convinced their 45-year-old dad to use minoxidil and finasteride, resulting in significant hair regrowth. The dad now uses 1mg of finasteride daily and topical minoxidil twice a day, and has also started using 1% ketoconazole shampoo.

community A New Therapeutic Channel to Come Soon: Hair Follicle Sugar Metabolism and Aldose Reductase

in Research/Science 131 upvotes 3 years ago

Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.

community ‘Long term use of fin/dut may be associated with health risks including fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease and potential kidney disease.’

in Research/Science 22 upvotes 7 months ago

Long-term use of finasteride and dutasteride may be linked to health risks like fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and potential kidney disease. Some users believe the risks are low and the medications are generally safe.

community 57% increased chance of pattern hair loss independently associated with the consumption of sugary beverages in men (p<0.001) Pt 2

in Research/Science 479 upvotes 7 months ago

Sugary beverages increase the risk of pattern hair loss in men by 57%. Treatments discussed include Minoxidil, finasteride, and RU58841.

Similar Research

5 / 1000+ results

The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome

Effect of Type 2 Diabetes Mellitus on the Pharmacokinetics of Metformin in Obese Pregnant Women

Research cited in this study

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

Related Community Posts Join

community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

community Detailed 6 months update for FUE HT and 4 years of FIN-MIN journey

community Convinced dad to get into minox 3 months ago and fin 2 months ago

community A New Therapeutic Channel to Come Soon: Hair Follicle Sugar Metabolism and Aldose Reductase

community ‘Long term use of fin/dut may be associated with health risks including fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease and potential kidney disease.’

community 57% increased chance of pattern hair loss independently associated with the consumption of sugary beverages in men (p<0.001) Pt 2

Similar Research

research The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome

research Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline

research Compendium of Polycystic Ovarian Syndrome and Its Relevance in Glycation and Diabetes

research Comprehensive Overview of Polycystic Ovary Syndrome

research Recognizing Polycystic Ovary Syndrome in the Primary Care Setting